Introduction
============

Non-fasting postprandial triglyceride (TG) concentrations are more effective at predicting cardiovascular risk than fasting TG concentrations; this association is independent of traditional coronary risk factors ([@b1-etm-09-01-0084],[@b2-etm-09-01-0084]). TG-rich lipoproteins, including chylomicrons assembled by TGs, dietary cholesterol and apolipoprotein B-48 (apoB-48), are extremely atherogenic and contribute to coronary heart disease development ([@b3-etm-09-01-0084]). Even in normolipidemic individuals, postprandial hypertriglyceridemia contributes to the generation of proinflammatory cytokines and oxidative stress, causing endothelial dysfunction ([@b4-etm-09-01-0084],[@b5-etm-09-01-0084]). Thus, the identification of novel therapeutic approaches to target postprandial lipid concentrations is of significant interest.

Vildagliptin is a selective inhibitor of dipeptidyl peptidase-4 (DPP4) and has been demonstrated to reduce the fasting and postprandial glucose levels in patients with type 2 diabetes, possibly by inhibiting the inactivation of glucagon-like peptide-1 (GLP-1) ([@b6-etm-09-01-0084]--[@b8-etm-09-01-0084]). Clinical studies have revealed that the long-term administration of DPP4 inhibitors improves the postprandial atherogenic levels of TG-rich lipoprotein and/or endothelial dysfunction in patients with type 2 diabetes and healthy volunteers ([@b9-etm-09-01-0084]--[@b11-etm-09-01-0084]). However, Ayaori *et al* reported that the effects of other DPP4 inhibitors attenuated endothelial dysfunction in patients with type 2 diabetes ([@b12-etm-09-01-0084]). Thus, the difference in effects on endothelial function among DPP4 inhibitors remains controversial. Furthermore, following long-term treatment with DPP4 inhibitors, the discrimination between the acute and chronic effects of vildagliptin is difficult.

α-glucosidase inhibitors, which lower postprandial plasma glucose levels by delaying the absorption of sugars from the digestive system, are used widely in the treatment of type 2 diabetes. A previous study also showed that treatment with voglibose improves endothelial function in type diabetes mellitus ([@b13-etm-09-01-0084]). Another study investigated the effect of voglibose on postprandial triglyceridemia following a meal test, but failed to show the benefit of voglibose compared with the placebo ([@b14-etm-09-01-0084]). The aim of the present study was to examine the postprandial effects of a single administration of vildagliptin and voglibose, an α-glucosidase inhibitor, on endothelial dysfunction and the lipid profile in normal individuals.

Materials and methods
=====================

Participants and study design
-----------------------------

The procedures carried out in the present study were approved by the Ethics Committee of Okayama Rohsai Hospital (Okayama, Japan) and written informed consent was obtained from all volunteers prior to the study commencement. The study procedures conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected by the *a priori* approval of the Ethics Committee of the hospital. The study was a randomized, double-blind, cross-over study ([Fig. 1](#f1-etm-09-01-0084){ref-type="fig"}), and all procedures were carried out at the Okayama Rohsai Hospital. A total of 11 volunteers were recruited through clinical study sites and community outreach between September and November 2012. A single dose of vildagliptin (50 mg; Novartis Pharmaceuticals Co., Tokyo, Japan) or voglibose (0.3 mg; Takeda Pharmaceutical Co Ltd, Tokyo, Japan) was administered and a one-week washout period was implemented prior to the administration of the second drug. The drugs were administered in a random order. All volunteers underwent medical check-ups and family histories were obtained in medical interviews. None of the 11 participants had hypertension, impaired glucose tolerance, dyslipidemia, or cerebrovascular or cardiovascular disease. The pre-specified primary outcome measure was the difference in the decrease in brachial artery flow-mediated dilation (FMD) following the cookie-loading test, and the secondary outcome measure was the difference in lipids profiles following the cookie-loading test.

Cookie-loading test procedure
-----------------------------

Following overnight fasting for ≥8--12 h, one tablet of vildagliptin or voglibose was taken 1 h prior to the cookie-loading test. The cookie consisted of 75 g carbohydrate, 28.5 g fat and 8 g protein with a total of 592 kcal per carton (Saraya Co., Osaka, Japan). Participants were instructed to consume the cookie with water within 20 min. Time measurements were initiated when half the cookie had been consumed. Biological parameters in the blood and endothelium-dependent FMD were assessed during fasting and 1.5 and 3 h after the cookie-loading test.

Measurement of biochemical parameters
-------------------------------------

The following parameters were measured in the blood by SRL Inc., (Tokyo, Japan) in the state of fasting prior to cookie ingestion: Serum total cholesterol (total-C), TG, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apoB-48, glucagon, GLP-1, insulin, hemoglobin A1c and glucose levels. Serum levels of total-C, TG, LDL-C, apoB-48, GLP-1, glucagon, insulin and glucose were measured 1.5 and 3 h after the cookie-loading test.

Measurement of FMD
------------------

During fasting and 1.5 and 3 h after cookie ingestion, measurements of FMD were performed by the same technician who was blinded to the study design and medication status. FMD was assessed as a parameter of vasodilation according to the guidelines for ultrasound assessment of FMD of the brachial artery using a 10-MHz linear array transducer probe (Unex Co., Nagoya, Japan) ([@b11-etm-09-01-0084]). Longitudinal images of the brachial artery at baseline were recorded with a stereotactic arm and the artery diameter was measured following supine rest for ≥5 min. The diameter of the artery was measured from the clear anterior (media-adventitia) and posterior (intima-media) interfaces, which were manually determined. Suprasystolic compression (50 mmHg higher than the systolic blood pressure) was subsequently performed on the right forearm for 5 min and measurements of the artery diameter were made continuously from 30 sec before to ≥2 min after cuff release. Maximum vasodilation was evaluated from the change in artery diameter following release from occlusion (%FMD).

Statistical analysis
--------------------

The sample size was determined based on the estimated FMD reported in a recent study ([@b11-etm-09-01-0084]). It was assumed that the mean improvement in postprandial %FMD was 2.7% and that the standard deviation was 2.0%. To use a two-sided test for differences, a minimal sample size of 10 individuals was required in each group to detect statistical differences in %FMD with a power of 80% and an α-type error of 5%. Results are expressed as the mean ± standard error. Differences in lipid profile and endothelial function between the two groups were compared using the Wilcoxon signed-rank test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

A total of 11 volunteers (seven males and four females) were recruited. The mean age and body mass index of the volunteers was 32±2 years and 22.0±0.7 kg/m^2^, respectively. Participants maintained their weight throughout the study period.

The comparison of postprandial endothelial function, which was assessed as the %FMD, between the vildagliptin and voglibose groups is shown in [Table I](#tI-etm-09-01-0084){ref-type="table"}. In the voglibose group, the postprandial %FMD decreased significantly until 3 h; however, the decrease in postprandial %FMD in the vildagliptin group was higher compared with that in the voglibose group (9.7±0.9 vs. 7.2±0.7%, respectively; [Table I](#tI-etm-09-01-0084){ref-type="table"}). The changes in the %FMD are shown in [Table I](#tI-etm-09-01-0084){ref-type="table"} and [Fig. 2A](#f2-etm-09-01-0084){ref-type="fig"}. The change in the %FMD from baseline to 3 h was significantly lower in the vildagliptin group compared with that in the voglibose group (−1.6±0.9 vs. −4.0±0.7%, respectively; P=0.01; [Fig. 2A](#f2-etm-09-01-0084){ref-type="fig"}).

The levels of lipid/lipoprotein, glucose, glucagon, GLP-1 and insulin in the postprandial state are shown in [Table I](#tI-etm-09-01-0084){ref-type="table"} and [Fig. 2](#f2-etm-09-01-0084){ref-type="fig"}. The level of apoB-48 1.5 h after the cookie-loading test in the vildagliptin group was significantly lower compared with that in the voglibose group. The levels of GLP-1 1.5 and 3 h after cookie ingestion in the vildagliptin group were significantly higher than those in the voglibose group. Changes in the levels of lipid/lipoprotein, glucose, glucagon, GLP-1 and insulin following the cookie-loading test are shown in [Fig. 2](#f2-etm-09-01-0084){ref-type="fig"} and [Table I](#tI-etm-09-01-0084){ref-type="table"}. The change in the level of TG from baseline to 3 h was significantly lower in the vildagliptin group compared with that in the voglibose group. The change in the level of GLP-1 from baseline to 3 h was significantly higher in the vildagliptin group than that in the voglibose group. The changes in the levels of apoB-48, glucose, glucagon and insulin from baseline to 3 h did not significantly differ between the vildagliptin and voglibose groups.

Discussion
==========

The results of the present study demonstrated that a single administration of vildagliptin significantly attenuated postprandial endothelial dysfunction (which was induced by a standard meal loading test) when compared with voglibose and that vildagliptin reduced postprandial levels of TG.

Our previous study revealed that alogliptin treatment for one week ameliorated postprandial hypertriglyceridemia and endothelial dysfunction in non-diabetic individuals ([@b11-etm-09-01-0084]). Other studies have demonstrated that treatment with vildagliptin for four weeks and sitagliptin for six weeks decreased the postprandial levels of TG and apoB-48 following a fat-loading test in patients with type 2 diabetes ([@b9-etm-09-01-0084],[@b10-etm-09-01-0084]). However, the present study is, to the best of our knowledge, the first to demonstrate that a single administration of vildagliptin reduces the postprandial increase in TG that accompanies postprandial endothelial dysfunction in healthy individuals. Following long-term treatment with DPP4 inhibitors, the discrimination between the acute and chronic effects of vildagliptin is difficult. The present study clearly demonstrated the acute effects of vildagliptin on postprandial endothelial dysfunction and hypertriglyceridemia.

There are several possible mechanisms underlying the effect of vildagliptin on postprandial endothelial dysfunction and hypertriglyceridemia. Regarding the attenuation of endothelial dysfunction, the increased expression of GLP-1 induced by vildagliptin may directly protect endothelial cells from hypertriglyceridemia. Clinical studies have demonstrated that GLP-1 analogs improve endothelial function in patients with type 2 diabetes ([@b15-etm-09-01-0084]--[@b17-etm-09-01-0084]). An experimental study reported that GLP-1 activated endothelial nitric oxide synthase in endothelial cells ([@b18-etm-09-01-0084]). Regarding the attenuation of hypertriglyceridemia, one study demonstrated that GLP-1 affected intestinal TG absorption ([@b19-etm-09-01-0084]), possibly by inhibiting gastric lipase ([@b20-etm-09-01-0084]). Another study has shown that GLP-1 may directly regulate lipoprotein assembly or the secretion of chylomicron in enterocytes ([@b21-etm-09-01-0084]).

A number of previous studies have demonstrated that treatment with α-glucosidase inhibitors, including acarbose or miglitol, for \>3 months improves postprandial endothelial dysfunction in patients with diabetes or coronary artery disease ([@b22-etm-09-01-0084],[@b23-etm-09-01-0084]). However, only one study reported that a single administration of miglitol significantly improved postprandial glucose and lipid metabolism and incretin secretion, and attenuated endothelial dysfunction in patients with diabetes following a standard meal loading; no favorable effects were observed following the administration of voglibose or a placebo ([@b14-etm-09-01-0084]). Despite the fact that the present study lacked a placebo group, the previous results support the findings of the current study that a single administration of vildagliptin significantly reduced the increase in TG following the cookie-loading test.

The present study had several important limitations. Firstly, the number of participants was small and therefore selection bias may have occurred. Secondly, no standardized method for assessing postprandial hypertriglyceridemia has been established. Thus, a range of fat-loading tests, including an oral fat meal, fat cream intake and intravenous fat loading, have been used in previous studies ([@b14-etm-09-01-0084],[@b24-etm-09-01-0084]). The present study utilized the cookie-loading test, which provided sufficient information regarding glucose intolerance and postprandial hypertriglyceridemia ([@b11-etm-09-01-0084]). Although the cookie provided a fixed amount of fat (28.5 g) per individual, the amount of fat administered per body surface area was not regulated. Therefore, the contribution of the fat metabolism of each individual cannot be excluded as an influential factor.

In conclusion, the present study compared the postprandial effects of vildagliptin and voglibose on endothelial dysfunction and lipid profiles. It was demonstrated that a single administration of the DPP4 inhibitor vildagliptin was effective at ameliorating the postprandial endothelial dysfunction, accompanied by a reduction in the postprandial elevation of TG. Vildagliptin shows potential as a drug to target cardiovascular disease by ameliorating endothelial dysfunction in the postprandial state, even in low-risk individuals.

![Study design. The present study was a randomized, double-blind, cross-over design. Prior to each cookie-loading test, 50 mg vildagliptin or 0.3 mg voglibose were administered in a blinded manner.](ETM-09-01-0084-g00){#f1-etm-09-01-0084}

![Effects of vildagliptin or voglibose treatment on changes in postprandial levels of (A) FMD, (B) glucose, (C) TG, (D) apoB-48, (E) GLP-1, (F) insulin and (G) glucagon in 11 individuals. Data are presented as the mean ± standard error. FMD, flow-mediated dilation; TG, triglyceride; apoB-48, apolipoprotein B-48; GLP-1, glucagon-like peptide-1.](ETM-09-01-0084-g01){#f2-etm-09-01-0084}

###### 

Lipid profile, apolipoprotein B-48, glucose, glucagon, GLP-1, insulin and %FMD measurements after the cookie test.

  A, Biochemical parameters                                                                         
  ----------------------------- ---------- -------------------------------------------------------- -------------------------------------------------------
  Total-cholesterol (mg/dl)                                                                         
   Voglibose                    188±11     180±11                                                   175±15
   Vildagliptin                 190±13     192±13                                                   187±12
  LDL-cholesterol (mg/dl)                                                                           
   Voglibose                    114±11     107±10                                                   110±10
   Vildagliptin                 110±13     113±14                                                   107±12
  HDL-cholesterol (mg/dl)                                                                           
   Voglibose                    58±3       57±3                                                     56±3
   Vildagliptin                 60±3       60±3                                                     59±3
  Triglyceride (mg/dl)                                                                              
   Voglibose                    98±17      124±26                                                   149±26
   Vildagliptin                 94±15      108±15                                                   122±18
  Apolipoprotein B-48 (μg/ml)                                                                       
   Voglibose                    4.9±1.0    6.3±0.9                                                  7.2±1.2
   Vildagliptin                 4.0±0.6    5.4±0.7[a](#tfn2-etm-09-01-0084){ref-type="table-fn"}    5.5±0.7
  Glucose (mg/dl)                                                                                   
   Voglibose                    98±2       115±6                                                    101±4
   Vildagliptin                 97±2       113±5                                                    101±5
  Glucagon (pg/ml)                                                                                  
   Voglibose                    71±8       68±9                                                     72±9
   Vildagliptin                 76±8       61±8                                                     69±9
  GLP-1 (pmol/l)                                                                                    
   Voglibose                    3.4±0.7    7.7±1.5                                                  6.3±1.1
   Vildagliptin                 4.6±0.9    11.0±1.7[a](#tfn2-etm-09-01-0084){ref-type="table-fn"}   9.0±1.1[a](#tfn2-etm-09-01-0084){ref-type="table-fn"}
  Insulin (μU/ml)                                                                                   
   Voglibose                    5.2±0.7    34.5±5.2                                                 18.2±3.5
   Vildagliptin                 6.3±0.9    34.3±5.4                                                 20.0±4.3
                                                                                                    
  B, Endothelial function                                                                           
                                                                                                    
  Parameter                     Fasting    1.5 h                                                    3 h
                                                                                                    
  FMD (%)                                                                                           
   Voglibose                    11.2±1.2   7.0±1.0                                                  7.2±0.7[a](#tfn2-etm-09-01-0084){ref-type="table-fn"}
   Vildagliptin                 11.3±1.3   7.8±1.0                                                  9.7±0.9

Data are presented as the mean ± standard error or frequency count (percentages), as appropriate.

P\<0.05 vs. the voglibose group.

LDL, low-density lipoprotein; HDL, high-density lipoprotein; GLP-1, glucagon-like peptide-1; FMD, flow-mediated dilation.
